A Phase 2 interventional study of sapropterin and Placebo in Autistic Disorder, sponsored by The Children's Health Council. Completed at 1 site in United States. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by The Children's Health Council · Phase 2, Interventional, and Treatment
This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in core symptoms of autism in young individuals, under age 6 years. The study will entail a double-blind, placebo-controlled 16-week intervention.
Over the past 20 years, several studies have suggested that sapropterin (tetrahydrobiopterin) might ameliorate core symptoms of autism at least in young (under age 6) subjects. However, those studies had somewhat questionable methodologies, a major one being that the doses of sapropterin used were roughly one tenth that thought to be needed to provide physiologically meaningful increases of sapropterin in the central nervous system (CNS). This study will look at the impact of a sustained exposure to this higher dose in well-diagnosed young children with autism.
1,360 studies on the registry are indexed under Autistic Disorder; 332 are open to participants now.
This study's enrollment of 46 is close to the median of 46 across 1,058 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →The Children's Health Council is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
Drug: sapropterin
The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
Drug: Placebo
Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
Also known as: Kuvan, tetrahydrobiopterin
Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
Also known as: sugar pill
Clinical Global Impression -- Improvement (CGI-I) Scale
The CGI-I assessed the number of participants showing much or very much improvement on the CGI-I scale. This is a summary judgment made by a trained clinician based on observed and reported behaviors of the child compared to baseline. It is a 7-point scale from very much worse (1) to very much improved (7). Chi-square analyses were used to assess change in CHI-I scores (by group, post-test). Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time
Time frame: Weekly for 4 weeks, then monthly, with 16-week end point. Primary outcome assessment used two time points, baseline and 16 weeks.
Clinical Global Impression -- Severity (CGI-S) Scale
The CGI-S assessed the number of participants with improved severity illness on the CGI-S scale. This is a summary judgment made by a trained clinician of symptom severity. It is a 7-point scale that rates the severity of the patient's illness at time of assessment with 1 - normal, not at all, to 7 - extremely ill. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time
Time frame: Baseline, 8 weeks, and 16 weeks. Primary outcome assessment used 2 time points, baseline and 16 weeks.
Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months.
Measures expressive \& receptive language and total scores in ages birth to 6 years 11 months. The scales generate raw, standard, and age-equivalent scores; raw scores for the total scale were selected for use in this study. Total is average of subscales. Minimum raw score = 0, maximum = 130. Higher scores indicate better language abilities. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. For the outcome effect, the difference between baseline and 16 weeks was determined as an indicator for change.
Time frame: Primary outcome assessment examined the difference in scores between baseline and week 16.
Vineland Adaptive Behavior Scale-II.
the Vineland-2 is a semi-structured interview designed to assess communicatino, daily living, socialization and motor skills. The Vineland-2 is comprised of a total Adaptive Composite scale; we chose to use 10 subscales that specifically address functional domains relevant for a young ASD sample - Receptive Communication, Expressive Communication, Personal Daily Living Skills, Domestic Daily Living Skills, Community Daily Living Skills, Interpersonal Relations, Play Skills, Coping Skills, Gross Motor Skills, Fine Motor Skills. Scales generate raw or sum, V-, and age-equivalent scores; raw scores were selected for use in the study. Raw score ranges from 0 to 108 depending on the scale. Total raw scale range is from 0 to 766. Subscale scores are averaged to create the total adaptive behavior composite. Higher subscale scores indicate more skills. Difference between baseline and week 16 was used as an indicator of change.
Time frame: Primary outcome assessment used two time points, baseline and 16 weeks.
Children's Yale Brown Obsessive Compulsive Scale (C-YBOCS)
The C-YBOCS is a scale is designed to rate the severity of obsessive and compulsive symptoms in children and adolescents, ages 6 to 17 years. It can be administered by a clinican or trained interviewer in a semi-structured fashion. In general, the ratings depend on the child's and parent's report; however, the final rating is based on the clinical judgement of the interviewer. Rate the characteristics of each item over the prior week up until, and including, the time of the interview. Scores should reflect the average of each item for the entire week, unless otherwise specified.
Time frame: Baseline, 8 weeks, and 16 weeks
Connor's Preschool ADHD Questionnaire
Conners Early Childhood, addresses child behavior for ages 2 years to 6 years with a variety of scales, including an ADHD subdomain.
Time frame: Baseline, 8 weeks, and 16 weeks
Adverse Events Scale
This was not a standardized scale but a set of questions that was asked of each family - some standard and others open ended.
Time frame: Every 1-2 weeks for 16 weeks
Aberrant Behavior Checklist (ABC) - Inappropriate Speech
Subscale assessing echolalia \& other odd speech. Higher subscale scores indicate more symptoms. 4 items comprise the subscale, with range of scores from 0-4. Total score range on this subscale is 0 to 16. Scores are averaged to compute overall score. Difference in scores between baseline and week 16 were used as indicator of change.
Time frame: Primary outcome assessment used two time points, baseline and 16 weeks.
Social Responsiveness Scale (SRS)
The SRS is a 65-item scale used to measure the severity of symptoms in ASD as they occur in natural social settings. The SRS is comprised of 1 Total scale and 5 subscales that generate raw scores that can be converted to standard T-scores (with mean of 50 and standard deviation of 10) for gender and rater type; standard scores were selected for use in this study. A total T-score of 76 or higher is considered severe and strongly associated with a clinical diagnosis of autistic disorder. A t-score of 60-75 is in the mild to moderate range and considered typical for children with mild or 'high-functioning' ASD, while a T-score of 59 or less suggests an absence of ASD symptoms. A total raw score of \>75 were associated with a sensitivity value of .85 and a specificity value of .75 for ASD. Difference in scores between baseline and week 16 were used as an indicator of change.
Time frame: Primary outcome assessment used two time points, baseline and 16 weeks.
Parent Global Assessment (PGA) Scale
This is a measure where parents rate their impression of their child's improvement, in a global manner.
Time frame: Baseline, 8 weeks, and 16 weeks
Recruitment spanned from 4/09 to 6/11. A variety of methods were used to advertise the study, but most successful recruitment was word-of-mouth from study participants.
| Milestone | Sapropterin | Placebo |
|---|---|---|
| Started | 23 | 23 |
| Completed | 20 | 22 |
| Not completed | 3 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Adverse event | 2 | 0 |
The CGI-I assessed the number of participants showing much or very much improvement on the CGI-I scale. This is a summary judgment made by a trained clinician based on observed and reported behaviors of the child compared to baseline. It is a 7-point scale from very much worse (1) to very much improved (7). Chi-square analyses were used to assess change in CHI-I scores (by group, post-test). Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time
| participants | Sapropterin | Placebo |
|---|---|---|
| Clinical Global Impression -- Improvement (CGI-I) Scale | 5 | 3 |
The CGI-S assessed the number of participants with improved severity illness on the CGI-S scale. This is a summary judgment made by a trained clinician of symptom severity. It is a 7-point scale that rates the severity of the patient's illness at time of assessment with 1 - normal, not at all, to 7 - extremely ill. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time
| participants | Sapropterin | Placebo |
|---|---|---|
| Clinical Global Impression -- Severity (CGI-S) Scale | 3 | 1 |
Measures expressive \& receptive language and total scores in ages birth to 6 years 11 months. The scales generate raw, standard, and age-equivalent scores; raw scores for the total scale were selected for use in this study. Total is average of subscales. Minimum raw score = 0, maximum = 130. Higher scores indicate better language abilities. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. For the outcome effect, the difference between baseline and 16 weeks was determined as an indicator for change.
| units on a scale | Sapropterin | Placebo |
|---|---|---|
| Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months. | 84 ± 29 | 60 ± 25 |
the Vineland-2 is a semi-structured interview designed to assess communicatino, daily living, socialization and motor skills. The Vineland-2 is comprised of a total Adaptive Composite scale; we chose to use 10 subscales that specifically address functional domains relevant for a young ASD sample - Receptive Communication, Expressive Communication, Personal Daily Living Skills, Domestic Daily Living Skills, Community Daily Living Skills, Interpersonal Relations, Play Skills, Coping Skills, Gross Motor Skills, Fine Motor Skills. Scales generate raw or sum, V-, and age-equivalent scores; raw scores were selected for use in the study. Raw score ranges from 0 to 108 depending on the scale. Total raw scale range is from 0 to 766. Subscale scores are averaged to create the total adaptive behavior composite. Higher subscale scores indicate more skills. Difference between baseline and week 16 was used as an indicator of change.
| units on a scale | Sapropterin | Placebo |
|---|---|---|
| Vineland Adaptive Behavior Scale-II. | 344.76 ± 50.0 | 294.9 ± 70.1 |
The C-YBOCS is a scale is designed to rate the severity of obsessive and compulsive symptoms in children and adolescents, ages 6 to 17 years. It can be administered by a clinican or trained interviewer in a semi-structured fashion. In general, the ratings depend on the child's and parent's report; however, the final rating is based on the clinical judgement of the interviewer. Rate the characteristics of each item over the prior week up until, and including, the time of the interview. Scores should reflect the average of each item for the entire week, unless otherwise specified.
No measurements were reported for this outcome.
Conners Early Childhood, addresses child behavior for ages 2 years to 6 years with a variety of scales, including an ADHD subdomain.
No measurements were reported for this outcome.
This was not a standardized scale but a set of questions that was asked of each family - some standard and others open ended.
No measurements were reported for this outcome.
Subscale assessing echolalia \& other odd speech. Higher subscale scores indicate more symptoms. 4 items comprise the subscale, with range of scores from 0-4. Total score range on this subscale is 0 to 16. Scores are averaged to compute overall score. Difference in scores between baseline and week 16 were used as indicator of change.
| units on a scale | Sapropterin | Placebo |
|---|---|---|
| Aberrant Behavior Checklist (ABC) - Inappropriate Speech | 2.6 ± 1.9 | 3.9 ± 3.6 |
The SRS is a 65-item scale used to measure the severity of symptoms in ASD as they occur in natural social settings. The SRS is comprised of 1 Total scale and 5 subscales that generate raw scores that can be converted to standard T-scores (with mean of 50 and standard deviation of 10) for gender and rater type; standard scores were selected for use in this study. A total T-score of 76 or higher is considered severe and strongly associated with a clinical diagnosis of autistic disorder. A t-score of 60-75 is in the mild to moderate range and considered typical for children with mild or 'high-functioning' ASD, while a T-score of 59 or less suggests an absence of ASD symptoms. A total raw score of \>75 were associated with a sensitivity value of .85 and a specificity value of .75 for ASD. Difference in scores between baseline and week 16 were used as an indicator of change.
| units on a scale | Sapropterin | Placebo |
|---|---|---|
| Social Responsiveness Scale (SRS) | 76.7 ± 10.9 | 83.2 ± 10.4 |
This is a measure where parents rate their impression of their child's improvement, in a global manner.
No measurements were reported for this outcome.
Collected over Adverse events were monitored for the length of the study, i.e., 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sapropterin | — | 2/23 (8.7%) | 10/23 (43.5%) |
| Placebo | — | 1/23 (4.3%) | 14/23 (60.9%) |
| Event | Sapropterin | Placebo |
|---|---|---|
| transient viral rashSkin and subcutaneous tissue disorders | 2/23 | 0/23 |
| seizure disorderNervous system disorders | 0/23 | 1/23 |
| Event | Sapropterin | Placebo |
|---|---|---|
| irritablityPsychiatric disorders | 5/23 | 4/23 |
| difficulty sleepingNervous system disorders | 2/23 | 4/23 |
| Change in Bowel HabitsGastrointestinal disorders | 0/23 | 4/23 |
| repetitive behaviorsNervous system disorders | 1/23 | 2/23 |
| hyperactivityNervous system disorders | 2/23 | 1/23 |
| Age, Categorical(Participants) | Sapropterin | Placebo | Total |
|---|---|---|---|
| <=18 years | 23 | 23 | 46 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Sapropterin | Placebo | Total |
|---|---|---|---|
| Mean | 5 ± 1 | 5 ± 1 | 5 ± 1 |
| Sex: Female, Male(Participants) | Sapropterin | Placebo | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 20 | 18 | 38 |
| Region of Enrollment(participants) | Sapropterin | Placebo | Total |
|---|---|---|---|
| United States | 23 | 23 | 46 |
The record gives a start of Mar 2009, a primary completion of Aug 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapropterin
The Children's Health Council